Inspire Medical Systems (INSP) Projected to Post Earnings on Monday

Key Points

• Inspire Medical Systems will report Q1 2026 results after the close on Monday, May 4; analysts expect EPS of ($0.34) and $201.04 million in revenue, with the earnings call at 5:00 PM ET.
• In the prior quarter (reported Feb. 11) the company beat estimates with $1.65 EPS (vs. $0.69 expected) and $269.08M in revenue, and analysts project about $2 EPS for both the current and next fiscal years.
• INSP has a market cap of $1.62B, a P/E of 11.31 and a 52‑week range of $48.30–$163.35, and carries an average analyst rating of Hold with a $101.41 average target price.

Inspire Medical Systems (NYSE:INSP - Get Free Report) is expected to be releasing its Q1 2026 results after the market closes on Monday, May 4th. Analysts expect Inspire Medical Systems to post earnings of ($0.34) per share and revenue of $201.04 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 4, 2026 at 5:00 PM ET.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.96. The firm had revenue of $269.08 million for the quarter, compared to analyst estimates of $264.02 million. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The business's quarterly revenue was up 12.2% compared to the same quarter last year. During the same period last year, the company earned $1.15 EPS. On average, analysts expect Inspire Medical Systems to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $56.33 on Monday. The firm has a market cap of $1.62 billion, a P/E ratio of 11.31, a P/E/G ratio of 2.90 and a beta of 0.86. The business's 50 day moving average price is $57.18 and its 200-day moving average price is $80.29. Inspire Medical Systems has a fifty-two week low of $48.30 and a fifty-two week high of $163.35.

Institutional Trading of Inspire Medical Systems

Several hedge funds have recently bought and sold shares of INSP. Smartleaf Asset Management LLC grew its holdings in Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after purchasing an additional 205 shares during the period. Larson Financial Group LLC grew its holdings in Inspire Medical Systems by 21,266.7% during the third quarter. Larson Financial Group LLC now owns 641 shares of the company's stock valued at $48,000 after purchasing an additional 638 shares during the period. Quarry LP grew its holdings in Inspire Medical Systems by 695.1% during the fourth quarter. Quarry LP now owns 644 shares of the company's stock valued at $59,000 after purchasing an additional 563 shares during the period. Daiwa Securities Group Inc. grew its holdings in Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock valued at $60,000 after purchasing an additional 130 shares during the period. Finally, Parallel Advisors LLC grew its holdings in Inspire Medical Systems by 349.7% during the fourth quarter. Parallel Advisors LLC now owns 715 shares of the company's stock valued at $66,000 after purchasing an additional 556 shares during the period. Institutional investors own 94.91% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on INSP shares. Oppenheimer cut Inspire Medical Systems from an "outperform" rating to a "market perform" rating in a research note on Thursday, January 22nd. UBS Group set a $67.00 price objective on Inspire Medical Systems in a research note on Friday, February 13th. Truist Financial lowered their price objective on Inspire Medical Systems from $70.00 to $64.00 and set a "hold" rating for the company in a research note on Wednesday, April 15th. Morgan Stanley set a $60.00 price objective on Inspire Medical Systems in a research note on Wednesday, February 18th. Finally, Robert W. Baird set a $74.00 price objective on Inspire Medical Systems and gave the company a "neutral" rating in a research note on Thursday, February 12th. Five equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Inspire Medical Systems has an average rating of "Hold" and an average target price of $101.41.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.